

Product datasheet for TL305507V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

B7-2 (CD86) Human shRNA Lentiviral Particle (Locus ID 942)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: B7-2 (CD86) Human shRNA Lentiviral Particle (Locus ID 942)

Locus ID: 942

Synonyms: B7-2; B7.2; B70; CD28LG2; LAB72

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CD86 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001206924, NM 001206925, NM 006889, NM 175862, NM 176892, NM 006889.1,

NM 006889.2, NM 006889.3, NM 006889.4, NM 175862.1, NM 175862.2, NM 175862.3,

NM 175862.4, NM 001206924.1, NM 001206925.1, NM 176892.1, BC040261

UniProt ID: P42081

Summary: This gene encodes a type I membrane protein that is a member of the immunoglobulin

superfamily. This protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in

several transcript variants encoding different isoforms.[provided by RefSeq, May 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).